Making the undruggable druggable
Unlocking challenging drug targets for the development of next-generation therapeutics
Selected Collaborations
It all starts with the drug target.
The majority of drug targets are so-called membrane proteins, and these are inherently unstable and challenging to investigate. Or so they were, until now.
Our proprietary Salipro® technology stabilizes membrane proteins in their native forms, enabling them to be employed in drug discovery programs for therapeutic antibodies or small molecule drugs. Through our in-house and partnered pipelines, we drive the discovery of novel drugs.
Pushing drug development forward together
We work with top-tier pharma and biotech partners to unlock drug targets for drug development programs.
Pipeline
We are driving forward drug development in our partnered as well as internal pipelines.
News
Boehringer Ingelheim Advances Collaboration with Salipro Biotech by Exercising Option
2025-12-17
Salipro Biotech AB announced today that Boehringer Ingelheim has exercised its option for a Salipro®-enabled target under the Research and License Agreement signed earlier this year. This step marks an important progression in the collaboration aimed at enabling novel drug discovery through Salipro Biotech’s proprietary membrane protein stabilization technology.
This progress is the direct result of excellent teamwork from both sides. By working together to unlock challenging drug targets, the teams are successfully integrating the Salipro® platform into Boehringer Ingelheim’s research programs supporting the development of novel therapeutic solutions.
Novel Strategies for GPCR Antibody Discovery - Join the Webinar!
2025-11-25
Are you working on challenging membrane targets like GPCRs? Don’t miss this opportunity to learn from industry experts shaping the future of antibody development.
What you’ll learn:
Why GPCRs are critical yet difficult drug targets
How the Salipro® platform stabilizes membrane proteins in their native lipid environment
Strategies for applying phage display directly to stabilized GPCRs
Speakers:
Dr. Jens Frauenfeld (CEO, Salipro Biotech)
Dr. Paul Royle (Bio-Rad Laboratories)
Date: Tuesday, December 2
Time: 8:00 AM PST | 11:00 AM EST | 5:00 PM CET
Sign up here for free.
Learn how combining the Salipro® technology with phage display enables high-affinity antibodies for hard-to-hit targets.
Milestone Achieved
2025-11-24
We’re excited to share the first cryoEM-based 3D epitope mapping results for our next-generation CXCR4 antibodies, marking a major step toward new therapeutic options in oncology and immunology.
These antibodies from our collaboration with Bio-Rad Laboratories, combine high affinity, antagonistic functionality, and superior efficacy in migration and signaling assays.
Thanks to ATEM’s cryoEM expertise, these cryoEM structures allowed us to see exactly how these antibodies engage CXCR4, knowledge that accelerates rational design and innovation.
This milestone, powered by the synergy of the Salipro® technology, Bio-Rad’s Pioneer™ platform, and ATEM’s structural analysis, exemplifies how collaboration makes the undruggable druggable.
https://www.bio-rad-antibodies.com/pioneer-antibody-library.html